“French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting,” the researchers wrote in an abstract. “Depending on their clinical presentation, azithromycin was added to the treatment.” https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf
Chloroquine for the 2019 novel coronavirus SARS-CoV-2
https://www.sciencedirect.com/science/article/pii/S0924857920300662
“Hydroxychloroquine and chloroquine have been recommended by Chinese and South Korean health authorities for the treatment COVID-19.[31] In vitro studies in cell cultures demonstrated that hydroxychloroquine was more potent than chloroquine against SARS-CoV-2.[32][33]
“On March 17 after testing in several hospitals around Italy the Italian Pharmaceutical Agency has included hydroxychloroquine in the list of drugs with positive preliminary results for treatment of coronavirus disease 2019.[38]”
Hydroxychloroquine is an inexpensive drug that must be prescribed by medical professionals. Hydroxychloroquine (HCQ), sold under the brand name Plaquenil among others, is a medication used for the prevention and treatment of certain types of malaria. Specifically it is used for chloroquine sensitive malaria. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. Use only under a doctors care and instructions. There can be serious side effects.
————————–
References above thanks to Wikipedia
- Physicians work out treatment guidelines for coronavirus”. Korea Biomedical Review. 13 February 2020. Retrieved 18 March 2020. http://www.koreabiomed.com/news/articleView.html?idxno=7428
- Yao, Xueting; Ye, Fei; Zhang, Miao; Cui, Cheng; Huang, Baoying; Niu, Peihua; Liu, Xu; Zhao, Li; Dong, Erdan; Song, Chunli; Zhan, Siyan (9 March 2020). “In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)”. Clinical Infectious Diseases. doi:10.1093/cid/ciaa237. ISSN 1537-6591. PMID 32150618. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa237/5801998
- Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine. Int J Antimicrob Agents. 2020 Mar 16:105945. doi:10.1016/j.ijantimicag.2020.105945 PMID 32194152 (edited) https://www.sciencedirect.com/science/article/pii/S0924857920300959?via%3Dihub
38 “Azioni intraprese per favorire la ricerca e l’accesso ai nuovi farmaci per il trattamento del COVID-19”. Italian Medicines Agency (AIFA) (in Italian). 17 March 2020. Retrieved 18 March 2020.
https://en.wikipedia.org/wiki/Hydroxychloroquine
budbromley 